Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.

17 Jul 2012

Why is the incidence of gout increasing?

Gout has been described by the Daily Mail as something, “usually associated with port-swilling, over-fed elderly men of the 19th century”. (1) Recent research carried out at the Boston University School of Medicine, however, has found that the incidence of gout in the US is on the rise. (2) Thus, the condition is clearly not something that only affects this stereotype.

17 Jul 2012

St. Joseph Hospital initiates enrollment in Medtronic’s SYMPLICITY HTN-3 trial for hypertension

St. Joseph Hospital of Orange on July 11 enrolled its first patient as part of a national clinical trial conducted by Medtronic Inc. for a renal denervation procedure designed to eliminate treatment-resistant hypertension.

From Medtronic 16 Jul 2012

Health risks of egg donation for young females

News is just breaking in India about Sushma Pandey, a 17-year-old young woman who died in 2010, two days after her third "egg donation." Her death is being attributed to the procedures used to extract eggs from healthy, desirable young females like Ms. Pandey. These eggs are often resold to affluent westerners for use in commercial production of their children. Her post-mortem report states she had "one abrasion, four contusions and a blood clot in the head, plus six injection marks" as well as "congestion in the ovaries and uterus."

14 Jul 2012

TGen's customized procedure produces high amounts of exosomes for treatment of CKD

Researchers at the Translational Genomics Research Institute (TGen) have developed a method of isolating biospecimens that could lead to a less costly, less invasive and more accurate way of diagnosing chronic kidney disease, or CKD.

12 Jul 2012

Research finds new single-gene cause of chronic kidney disease

A new single-gene cause of chronic kidney disease has been discovered that implicates a disease mechanism not previously believed to be related to the disease, according to new research from the University of Michigan.

11 Jul 2012

Kidney treatment could affect mouth health

Study results indicate a positive association between the type of treatment modality chronic kidney disease patients receive and the likelihood for them having periodontitis.

10 Jul 2012

Measuring creatinine and cystatin C more accurately estimates kidney function

Measuring creatinine and cystatin C - two markers for chronic kidney disease (CKD) - more precisely estimates kidney function than either marker alone, according to a study funded by the National Institutes of Health. Results appear in the July 5 issue of the New England Journal of Medicine.

10 Jul 2012

Ampio announces results from Optina trial on DME

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), announced the significant results from their further analysis of its Optina trial on DME.

9 Jul 2012

Genkyotex closes CHF25M Series C extension

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.

9 Jul 2012

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.

29 Jun 2012

Anthera announces results from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus.

28 Jun 2012

Study finds increase in incidence of gout and hyperuricemia in the U.S.

Researchers from Boston University School of Medicine (BUSM) have found that the incidence of gout and hyperuricemia (high uric acid levels) in the U.S. has risen significantly over the last 20 years and is associated with major medical disorders like hypertension and chronic kidney disease.

27 Jun 2012

Chronic kidney disease is major risk factor for future coronary events

People with chronic kidney disease have a 10-year risk for myocardial infarction of around 12%, report researchers who found that this was higher than that for people with diabetes.

26 Jun 2012

New system provides comprehensive remote monitoring solution for the chronically ill

As Europe's population ages, chronic diseases are becoming increasingly widespread. Characterised by gradually deteriorating health and recurring incidents often requiring immediate medical attention, chronic illnesses have a severe impact on patients' autonomy and life quality and are putting increasing strain on over-stretched healthcare systems.

26 Jun 2012

Enrollment commences in Stealth Peptides' Bendavia Phase II clinical study for acute STEMI

Stealth Peptides Incorporated, a privately held biopharmaceutical company developing innovative therapies for cardiovascular disease and its complications, announced today that the first patient was enrolled in its multinational Phase II clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries for patients experiencing acute ST-segment elevation myocardial infarction.

25 Jun 2012

Standard aspirin dose may not protect diabetics against blood clots

Many patients with type 2 diabetes may be aspirin resistant. That means the standard aspirin dose may not protect them against blood clots that cause heart attacks and strokes among diabetics, a new clinical study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Diabetes is the number 1 cause of neuropathy, which is a very common condition in itself. In fact, up to half of all neuropathy is caused by diabetes, although other people can get the condition as well.

25 Jun 2012

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

AMAG Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).

23 Jun 2012

Largest study to examine impact of gastric sleeve surgery on pre-transplant obese patients

Morbidly obese patients with end-stage organ failure may improve their chances for successful organ transplantation after laparoscopic sleeve gastrectomy, according to a new study presented here at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).

21 Jun 2012